In-Vitro Growth Inhibition of Bacterial Pathogens by Probiotics and a Synbiotic: Product Composition Matters

• Published in: International journal of environmental research and public health Vol. 17; no. 9; p. 3332
• Main Authors: Piatek, Jacek, Krauss, Hanna, Ciechelska-Rybarczyk, Arleta, Bernatek, Malgorzata, Wojtyla-Buciora, Paulina, Sommermeyer, Henning
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 11.05.2020; MDPI
• Subjects: Antibiotics; Antimicrobial agents; Bacteria; Bacterial infections; Digestive system; E coli; Fructooligosaccharides; Infections; Inhibition; Kinases; Klebsiella; Microbiota; Microorganisms; Pathogens; Prebiotics; Probiotics; Product differentiation; Salmonella; Strains (organisms); Yeasts; Poland; United States > US; Germany; gut microbiome; pathogen overgrowth; antimicrobial activity
• ISSN: 1660-4601; 1661-7827; 1660-4601
• DOI: 10.3390/ijerph17093332

A variety of activities potentially contribute to the beneficial effects of probiotic bacteria observed in humans. Among these is a direct inhibition of the growth of pathogenic bacteria in the gut. The present study characterizes head-to-head the in-vitro pathogen growth inhibition of clinically relevant infectious bacterial strains by different types of probiotics and a synbiotic. In-vitro growth inhibition of and were determined. Investigated products were a yeast mono strain probiotic containing , bacterial mono strain probiotics containing either or , a multi strain probiotic containing three , and a multi strain synbiotic containing nine different probiotic bacterial strains and the prebiotic fructooligosaccharides (FOS). Inhibition of pathogens was moderate by and , medium by and the mixture and strong by the multi strain synbiotic. Head-to-head in-vitro pathogen growth inhibition experiments can be used to differentiate products from different categories containing probiotic microorganisms and can support the selection process of products for further clinical evaluation.